Medicare’s Payment Strategy For End-Stage Renal Disease Now Embraces Bundled Payment And Pay-For-Performance To Cut Costs

Lignende værker

• Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents
  af: Swaminathan, Shailender, et al.
  Udgivet: (2015)
• Initial Session Duration and Mortality Among Incident Hemodialysis Patients
  af: Swaminathan, Shailender, et al.
  Udgivet: (2017)
• Association of Mandatory Bundled Payments for Joint Replacement With Use of Postacute Care Among Medicare Advantage Enrollees
  af: Meyers, David J., et al.
  Udgivet: (2019)
• Erythropoietin-Stimulating Agents and Survival in End-Stage Renal Disease: Comparison of Payment Policy Analysis, Instrumental Variables, and Multiple Imputation of Potential Outcomes
  af: Dore, David D., et al.
  Udgivet: (2013)
• Association of Medicaid Expansion With 1-Year Mortality Among Patients With End-Stage Renal Disease
  af: Swaminathan, Shailender, et al.
  Udgivet: (2018)